CureVac has initiated a rolling review with the European Medicines Agency (EMA), working towards authorization for its mRNA COVID-19 vaccine in the European Union.
AbbVie and Caribou Biosciences have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics.
Global CDMO, Rentschler Biopharma, has announced today that it will build its ATMP capacity in the UK at the Cell and Gene Therapy (CGT) Catapult facility in Stevenage.
While some jurisdictions have limited the use of the Oxford University / AstraZeneca COVID-19 vaccine, the WHO says it can be used even where variants are known to be in circulation and with people aged 65+.
Announcing its financial results for 2020, AstraZeneca has said that it could take between six and nine months to develop shots that are effective against new variants of COVID-19.
AstraZeneca and IDT Biologika are exploring options to accelerate output of finished COVID-19 Vaccine AstraZeneca in the second quarter of 2021 in order to help support Europe’s immediate vaccination needs during the pandemic.
Collaboration is not an unknown in the domain of pharmaceutical development, but it is rare enough. The demands of the COVID-19 pandemic, however, have seen competitors switch to become manufacturing allies.
Three COVID-19 vaccine manufacturing sites are set to start production in France in the coming weeks: while the French government is seeking to boost further production with a €300m ($363m) initiative announced on Monday.
BioNTech announced this morning it has started the production of mRNA at its new facility in Marburg, Germany: which will become one of the largest mRNA manufacturing sites in Europe.
UK catalyst organization, CPI, has announced the launch of a project that aims to revolutionize the manufacture of oligonucleotides, through a collaboration involving, among others, AstraZeneca, Exactmer, and Novartis.
Health officials in Azerbaijan have granted approval for a clinical trial to take place in that country combining Russia’s Sputnik V vaccine with the Oxford-AstraZeneca COVID-19 shot in adults 18 years and older.
